Should You Buy SpaceX Stock Below $125 per Share? Here's What History Says.

Space Exploration Technologies (SPCX) has sold off since its recent IPO two months ago and is now below pre-IPO levels, despite a relatively modest first-year benchmark return reference of ~16% (vs. more explosive early performance expectations). The article highlights potential near-term overhang from investor insider lockup expirations at different times in 2026 and 2027, which could increase sell pressure and pressure demand. It concludes that investors should be patient rather than buy under $125 per share until after initial post-IPO dynamics settle (reassessing around mid-2027).

Analysis

The near-term setup is dominated by liquidity, not operating fundamentals. Freshly listed, story-driven names typically trade on position unwinds and narrative fatigue before they trade on unit economics, and multiple lockup windows create a natural supply ceiling that can suppress even good quarterly prints. That makes the first 6-12 months a poor period to chase; the market is likely to require repeated evidence of execution before assigning a premium multiple.

Second-order, the likely winners are more liquid public proxies that can absorb risk appetite if private-market enthusiasm cools: TSLA as the cleaner Musk-beta expression, and public space/defense comps like RKLB or LUNR as the tradeable way to own secular space exposure without the same supply overhang. The loser is any late-stage private-tech benchmark that depends on scarcity value; once insider stock becomes monetizable, the discount rate rises mechanically and secondary selling can pressure the whole cohort.

Catalysts over the next 1-3 months are the next earnings cadence and any signs of insider distribution. Over 6-18 months, the key question is whether operating growth can outrun the stock’s expanding float; if not, valuation can stay capped even with strong headline progress. The thesis is falsified if the stock reclaims and holds above the IPO range on two consecutive earnings beats with no visible selling pressure, indicating the market has already absorbed the supply overhang.

Contrarian view: the consensus may be overapplying Tesla-style compounding to a much more mature asset. Optionality is real, but scarcity is not a moat once the float expands; until the market sees repeated proof that growth is durable through lockup events, patience is the higher-expected-value stance.

Key Decisions for Investors

• Do not initiate a fresh long in SPCX for 3-6 months; wait for the first meaningful post-earnings/lockup supply wave to clear and for the stock to hold above its IPO range for at least 4-6 weeks.
• If SPCX borrow and derivatives are available, use any sharp post-earnings or lockup-related rallies to build a small tactical short; cover if the company delivers two straight quarters of accelerating revenue and no evidence of insider selling.
• Prefer TSLA over SPCX for any Musk-linked risk appetite trade; TSLA is the liquid, tradeable expression, while SPCX carries a structural float-overhang discount.
• For space exposure, rotate into public comps like RKLB or LUNR rather than chasing SPCX; these are cleaner vehicles if the market reallocates away from illiquid private names.
• Set an alert on secondary activity/lockup-expiry timing in 2026-2027; if sell pressure is lighter than expected, that is the trigger to reassess the short thesis.